Lot certificates published
Plain, secure packaging
Purely Peptides
Research Catalog

Compound class

GLP-1 receptor peptide analogs

Designed peptide analogs whose declared molecular relationship is agonism at the glucagon-like peptide-1 receptor.

Published: 2026-09-04Literature/identifier verification: 2026-08-23

01

Neutral class definition

Designed peptide analogs whose declared molecular relationship is agonism at the glucagon-like peptide-1 receptor.

02

Related compounds

Compound

Exenatide

Exenatide is synthetic exendin-4, a 39-residue peptide with an N-terminal histidine and a C-terminal serine amide; the natural peptide was isolated from Heloderma suspectum venom and characterized as a member of the glucagon superfamily. Horváth et al. (PMID 37528104) place the exendins among the gastrointestinal peptides of the glucagon family.

Exendin-4

Compound

Liraglutide

Liraglutide is an acylated peptide analog of glucagon-like peptide-1, characterized against the GLP-1 receptor.

NN2211

Compound

Semaglutide

Semaglutide is an acylated peptide analog of glucagon-like peptide-1. Its discovery record identifies two amino-acid substitutions and derivatization at Lys26.

NN9535 · NNC 0113-0217

03

Related molecular mechanisms

receptor

Glucagon-like peptide-1 receptor

GLP-1R is a class B G-protein-coupled receptor. The cited structural and pharmacology records characterize semaglutide and retatrutide as peptide agonists at this receptor.

04

Relevant glossary terms

AgonistLigandG-protein-coupled receptorPeptide analogLipidationAmidation

05

Verified bibliography

  1. Reference 1

    Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.

    Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J, Kofoed J, Madsen K, Knudsen LB, McGuire J, Steensgaard DB, Strauss HM, Gram DX, Knudsen SM, Nielsen FS, Thygesen P, Reedtz-Runge S, Kruse T

    Journal of medicinal chemistry · 2015-09-11 · Journal Article

    current
    PMID 26308095DOI 10.1021/acs.jmedchem.5b00726SemaglutideGLP-1R

  2. Reference 2

    Structure and dynamics of semaglutide- and taspoglutide-bound GLP-1R-Gs complexes.

    Zhang X, Belousoff MJ, Liang YL, Danev R, Sexton PM, Wootten D

    Cell reports · 2021-07-13 · Journal Article

    current
    PMID 34260945DOI 10.1016/j.celrep.2021.109374SemaglutideGLP-1R

  3. Reference 3

    The Discovery and Development of Liraglutide and Semaglutide.

    Knudsen LB, Lau J

    Frontiers in endocrinology · 2019-04-12 · Review

    current
    PMID 31031702PMC6474072DOI 10.3389/fendo.2019.00155SemaglutideGLP-1R

Study models of these references

What kind of experiment each cited paper reports, taken from its abstract unless marked. Not a summary of results.

ReferenceStudy models
Lau J et al. 2015Study models reported: in vitro; animal (mini-pig) · from the abstract
Zhang X et al. 2021Study models reported: in vitro · from the abstract
Knudsen LB et al. 2019Review article

06

Related Purely Peptides research articles

07

Related compound classes

Multi-receptor incretin analogsNonpeptide receptor agonists